Abstract
TOKYO-- This year, the U.S. Food and Drug Administration approved a phase II trial to test the efficacy of Kanglaite in treating non-small-cell lung cancer, making Kanglaite the first drug derived from a traditional Chinese herbal remedy to go into clinical trials in the United States. Asian governments are hoping that high-volume screening and rigorous clinical trials will unlock the secrets of ancient herbal remedies--and that the results will pass muster with Western scientists.

This publication has 0 references indexed in Scilit: